Journal
MOLECULAR CELL
Volume 67, Issue 1, Pages 128-+Publisher
CELL PRESS
DOI: 10.1016/j.molcel.2017.05.030
Keywords
-
Categories
Funding
- National Institute for Neurological Diseases and Stroke [NS73831]
- National Cancer Institute [F31CA186668]
- National Brain Tumor Society
- Ben and Catherine Ivy Foundation
- NIH [R01-GM116897, R35ca196878]
- American Cancer Society [RSG-16-111-01-MPC]
Ask authors/readers for more resources
Mutations in cancer reprogram amino acid metabolism to drive tumor growth, but the molecular mechanisms are not well understood. Using an unbiased proteomic screen, we identified mTORC2 as a critical regulator of amino acid metabolism in cancer via phosphorylation of the cystine-glutamate antiporter xCT. mTORC2 phosphorylates serine 26 at the cytosolic N terminus of xCT, inhibiting its activity. Genetic inhibition of mTORC2, or pharmacologic inhibition of the mammalian target of rapamycin (mTOR) kinase, promotes glutamate secretion, cystine uptake, and incorporation into glutathione, linking growth factor receptor signaling with amino acid uptake and utilization. These results identify an unanticipated mechanism regulating amino acid metabolism in cancer, enabling tumor cells to adapt to changing environmental conditions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available